{"id":684795,"date":"2022-09-13T12:03:20","date_gmt":"2022-09-13T16:03:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/"},"modified":"2022-09-13T12:03:20","modified_gmt":"2022-09-13T16:03:20","slug":"ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/","title":{"rendered":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n LOS ANGELES<\/span>
\n <\/span>, Sept. 13, 2022<\/span><\/span> \/PRNewswire\/ — Glancy Prongay<\/span> & Murray LLP<\/a> (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE).<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Glancy
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Class Period: <\/b>
\n December 29, 2020<\/span> \u2013 August 3, 2022<\/span>
Lead Plaintiff Deadline:<\/b>October 17, 2022<\/span><\/p>\n

If you wish to serve as lead plaintiff of the Ampio lawsuit, you can submit your contact information at www.glancylaw.com\/cases\/ampio-pharmaceuticals-inc-1\/<\/a>. You can also contact Charles H. Linehan<\/span>, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com<\/a> to learn more about your rights.<\/p>\n

The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a Biologics License Application for Ampion; (2) inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis at all relevant times.<\/p>\n

Follow us for updates on LinkedIn<\/a>, Twitter<\/a>, or Facebook<\/a>.<\/p>\n

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to\u00a0learn more\u00a0about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire<\/span>, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California<\/span> 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com<\/a>, or visit our website at www.glancylaw.com<\/a>.\u00a0 If you inquire by email please include your mailing address, telephone number and number of shares purchased.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n

\n Contacts
<\/b>
\n Glancy Prongay<\/span> & Murray LLP, Los Angeles<\/span>
Charles Linehan<\/span>, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com<\/a>
www.glancylaw.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-301623285.html<\/a><\/p>\n

SOURCE Glancy Prongay<\/span> & Murray LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LOS ANGELES , Sept. 13, 2022 \/PRNewswire\/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE). Class Period: December 29, 2020 \u2013 August 3, 2022Lead Plaintiff Deadline:October 17, 2022 If you wish to serve as lead plaintiff of the Ampio lawsuit, you can submit your contact information at www.glancylaw.com\/cases\/ampio-pharmaceuticals-inc-1\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a … <\/p>\n

Continue reading “AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-684795","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LOS ANGELES , Sept. 13, 2022 \/PRNewswire\/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE). Class Period: December 29, 2020 \u2013 August 3, 2022Lead Plaintiff Deadline:October 17, 2022 If you wish to serve as lead plaintiff of the Ampio lawsuit, you can submit your contact information at www.glancylaw.com\/cases\/ampio-pharmaceuticals-inc-1\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a … Continue reading "AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T16:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1219482\/Glancy_Prongay_and_Murray_LLP.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit\",\"datePublished\":\"2022-09-13T16:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/\"},\"wordCount\":369,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1219482\\\/Glancy_Prongay_and_Murray_LLP.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/\",\"name\":\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1219482\\\/Glancy_Prongay_and_Murray_LLP.jpg\",\"datePublished\":\"2022-09-13T16:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1219482\\\/Glancy_Prongay_and_Murray_LLP.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1219482\\\/Glancy_Prongay_and_Murray_LLP.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/","og_locale":"en_US","og_type":"article","og_title":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire LOS ANGELES , Sept. 13, 2022 \/PRNewswire\/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE). Class Period: December 29, 2020 \u2013 August 3, 2022Lead Plaintiff Deadline:October 17, 2022 If you wish to serve as lead plaintiff of the Ampio lawsuit, you can submit your contact information at www.glancylaw.com\/cases\/ampio-pharmaceuticals-inc-1\/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. The complaint filed alleges that, throughout the Class Period, Defendants: (1) inflated the Company’s true ability to successfully file a … Continue reading \"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-13T16:03:20+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1219482\/Glancy_Prongay_and_Murray_LLP.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit","datePublished":"2022-09-13T16:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/"},"wordCount":369,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1219482\/Glancy_Prongay_and_Murray_LLP.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/","name":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1219482\/Glancy_Prongay_and_Murray_LLP.jpg","datePublished":"2022-09-13T16:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1219482\/Glancy_Prongay_and_Murray_LLP.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1219482\/Glancy_Prongay_and_Murray_LLP.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ampe-investors-have-opportunity-to-lead-ampio-pharmaceuticals-inc-securities-fraud-lawsuit-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AMPE Investors Have Opportunity to Lead Ampio Pharmaceuticals, Inc. Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=684795"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684795\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=684795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=684795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=684795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}